United States
Marea Holdings Ltd, founded by a team of leading experts and scientists, is dedicated to advancing new generations of medicines for cardioendocrine diseases. The company leverages large-scale human genetic data and the latest biological advancements to develop first-in-class treatments targeting critical, unaddressed genetic drivers of these diseases. Marea's clinical-stage pipeline includes novel therapies such as MAR001, an ANGPTL4 inhibitor, and MAR002, a GHR antagonist, which have the potential to serve as transformative treatment options for significant patient populations. Located in South San Francisco, California, Marea Therapeutics is a fast-growing company that recently presented positive Phase 1 data for MAR002 at the ENDO 2026 conference, demonstrating potential best-in-disease efficacy and dosing profile for the treatment of acromegaly.
Browsing, company names, locations and sectors are always free. A free account adds 5 contact releases every month — e-mail and phone, view or export. Need more? Contact packs start at 19 € for 50, or upgrade to a monthly plan.
Yes — no card required. Browsing is always free, and a free account adds 5 contact releases every month.
Your first 5 contact releases each month are included in the free account. After that, packs start at 19 € for 50 contacts (view or export), or a monthly plan for regular use.
Companies are harvested from the open web — registers, websites and industry directories — not self-registered sign-ups. Contact details are shown only once you use a release or credit, never invented.